Related Experiment Video

Updated: May 26, 2026

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
06:54

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

Published on: June 22, 2022

Matrix metalloproteinase 9 mRNA: an early prognostic marker for patients with acute stroke

Colin A Graham1, Rebecca W Y Chan, Dexter Y S Chan

  • 1Accident and Emergency Medicine Academic Unit, The Chinese University of Hong Kong, Main Clinical Block and Trauma Centre, Prince of Wales Hospital, Shatin, NT, Hong Kong SAR.

Clinical Biochemistry
|December 28, 2011
PubMed
Abstract

Insights

Matrix metalloproteinase 9 (MMP9) mRNA levels predict stroke outcomes. Higher MMP9 mRNA concentrations in stroke patients correlate with increased mortality and poorer functional recovery.

Area of Science:

  • Biomedical research
  • Molecular biology
  • Neurology

Background:

  • Stroke is a leading cause of death and disability worldwide.
  • Identifying reliable prognostic markers is crucial for stroke patient management.
  • Matrix metalloproteinase 9 (MMP9) is implicated in various pathological processes, including neuroinflammation and tissue remodeling.

Purpose of the Study:

  • To evaluate the potential of matrix metalloproteinase 9 (MMP9) mRNA as a prognostic biomarker in patients who have experienced a stroke.
  • To determine the association between MMP9 mRNA levels and clinical outcomes, including mortality and functional status.

Main Methods:

  • Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was employed to measure MMP9 mRNA concentrations.
  • The study cohort comprised 126 patients diagnosed with stroke.
  • MMP9 mRNA levels were correlated with patient survival and modified Rankin scale (mRS) scores.

Main Results:

  • MMP9 mRNA concentrations were significantly higher in non-surviving stroke patients compared to survivors (P=0.0002).
  • Patients with a post-stroke modified Rankin score (mRS) greater than 2 exhibited 1.9-fold higher MMP9 mRNA levels than those with mRS ≤ 2 (P<0.05).

Conclusions:

  • MMP9 mRNA serves as a significant predictor of poor prognosis and mortality in stroke patients.
  • Elevated MMP9 mRNA levels may indicate a higher risk of adverse outcomes following a stroke.
  • Further research could explore therapeutic strategies targeting MMP9 in stroke management.

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...